Pathophysiological changes that affect drug disposition in protein-energy malnourished children by Oshikoya, Kazeem A & Senbanjo, Idowu O
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Nutrition & Metabolism
Open Access Review
Pathophysiological changes that affect drug disposition in 
protein-energy malnourished children
Kazeem A Oshikoya*1,2,3 and Idowu O Senbanjo2
Address: 1Pharmacology Department, Lagos State University College of Medicine, PMB 21266, Ikeja, Lagos, Nigeria, 2Paediatrics Department, 
Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria and 3Academic Division of Child Health, University of Nottingham, The Medical 
School, Royal Derby Children's Hospital, Uttoxeter Road, Derby DE22 3DT, UK
Email: Kazeem A Oshikoya* - med_modhospital@yahoo.com; Idowu O Senbanjo - senbanjo001@yahoo.com
* Corresponding author    
Abstract
Protein-energy malnutrition (PEM) is a major public health problem affecting a high proportion of
infants and older children world-wide and accounts for a high childhood morbidity and mortality in
the developing countries. The epidemiology of PEM has been extensively studied globally and
management guidelines formulated by the World Health Organization (WHO). A wide spectrum
of infections such as measles, malaria, acute respiratory tract infection, intestinal parasitosis,
tuberculosis and HIV/AIDS may complicate PEM with two or more infections co-existing. Thus,
numerous drugs may be required to treat the patients. In-spite of abundant literature on the
epidemiology and management of PEM, focus on metabolism and therapeutic drug monitoring is
lacking. A sound knowledge of pathophysiology of PEM and pharmacology of the drugs frequently
used for their treatment is required for safe and rational treatment. In this review, we discuss the
pathophysiological changes in children with PEM that may affect the disposition of drugs frequently
used for their treatment. This review has established abnormal disposition of drugs in children with
PEM that may require dosage modification. However, the relevance of these abnormalities to the
clinical management of PEM remains inconclusive. At present, there are no good indications for
drug dosage modification in PEM; but for drug safety purposes, further studies are required to
accurately determine dosages of drugs frequently used for children with PEM.
Introduction
Protein-energy malnutrition (PEM) is generally a nutri-
tional problem that results from varying proportions of
protein and calorie deficiency in infants and young chil-
dren of developing countries [1]. It is a global public
health problem, affecting children from African, Asian,
Latin American and Caribbean regions [2-4]. Approxi-
mately 70% of the world's malnourished children live in
Asia [4]. PEM is directly or indirectly responsible for about
half of the 10.8 million deaths per year in under five chil-
dren in developing countries [5]. The major risk factors
that can predispose a child to having PEM include pov-
erty, lack of access to quality food, cultural and religious
food customs, poor maternal education, inadequate
breast feeding, and lack of quality healthcare [5-7]. In
addition to macronutrient deficiency, there is clinical
and/or subclinical deficiency of micronutrients [8].
The World Health Organization (WHO) has broadly clas-
sified PEM into underweight, wasting and stunting [9]
based on the physical status and anthropometric measure-
ments of a child in a given population. This method of
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classification is however more useful in epidemiological
studies of PEM in a large population of children [3,10].
Other methods of PEM classification have been used in
clinical studies [11]. Most of the previous studies that
evaluated drug disposition in children with PEM have
used the Gomez [12], Waterlow [13] and Wellcome Trust
Party [14] classifications. However, the Wellcome Trust
Party classification is widely used more frequently than
others in clinical studies of PEM. Apart from using the
anthropometric measurements; clinical symptoms and
signs, and findings from laboratory investigations are
additional criteria used in the classification PEM. Clini-
cally, PEM is a disease spectrum that can present as under-
weight, marasmus, marasmic-kwashiorkor or
kwashiorkor; the severe forms being marasmus, maras-
mic-kwashiorkor and kwashiorkor [8].
The pathophysiological changes in PEM are as a result of
the imbalance between nutrient supplies and require-
ments. These changes account for the clinical signs and
symptoms of PEM [15]. Protein deficiency and lack of
immune mediators is responsible for immunologic defi-
ciency in the humoral and cellular subsystem, which pre-
disposes a child with PEM to infections [16].
Carbohydrate deficiency can lead to abnormal lipid
metabolism which may manifest as marked reduction of
adipose tissue in a child with marasmus [17]. Lack of a
substrate (tyrosine amino acid) and coenzymes required
for the synthesis of pigments in the hair and skin result in
changes in the hair colour and hyperpigmentation of the
skin in marsamic-kwashiorkor and kwashiorkor [18].
Presences of aflatoxins and protein deficiency have been
implicated in the aetiology of oedema in kwashiorkor
rather than due to severe anaemia that was postulated in
the past [8,19].
PEM is usually associated with infections such as measles,
acute respiratory tract infection, malaria, HIV/AIDS and
tuberculosis [20]. The World Health Organization
(WHO) has recommended empirical treatment of all chil-
dren admitted for PEM with antibiotics because the signs
and symptoms of infection may be masked [21]. How-
ever, other specific associated infections would require
treatment with numerous drugs such as the more potent
antibiotics, antimalarials, antiretroviral and anti-tubercu-
losis drugs. The disposition of these drugs has not been
well studied in children with PEM.
Many of the physiological systems of children with PEM
are deranged and either directly or indirectly influence the
disposition of drugs frequently used for their treatment.
This review was therefore aimed at discussing the various
physiological derangements as they affect drug disposi-
tion in children with PEM.
Body fluid distribution
The total body water (TBW) is increased in proportion to
the degree of malnutrition [22]. Children with marasmus
have the highest TBW but contrarily, there is a significant
reduction in adipose mass as well as lean body mass in
marasmus and marasmic-kwashiorkor which can alter the
apparent volume of distribution of drugs [23]. The distri-
bution into adipose tissue of lipid soluble drugs is known
to be reduced in PEM [23]. A major clinical implication of
such reduction is that the concentration of the lipid solu-
ble drug would increase at the target tissues, thus prolong-
ing their pharmacodynamic actions.
Body fluid compartments are altered by many factors such
as nutritional status and disease [24]. The increased total
body water is associated with a proportionate rise in extra-
cellular fluid (ECF); this is seen particularly in children
with oedema [25].
Infection is a major complication of PEM and may occur
without the classical signs and symptoms. Consequently,
the WHO has recommended that all children admitted
with PEM should routinely receive parenteral antibiotics
[21]. Tissue penetration of antibiotics is very important in
the treatment of infections, since many infections are
located in deep tissues, or more specifically in the extracel-
lular tissue space [26]. Studies on antibiotics distribution
into the body fluids have shown that serum levels do not
necessarily reflect the concentration in deep tissues, which
is frequently 50% less [27]. A direct relationship between
an antibiotic dose (cefalotin) and the level achieved in the
interstitial fluids has been established in a study [28]. The
antibiotic concentrations in the serum and the interstitial
fluids showed the same time-concentration response irre-
spective of the dose.
The volume of distribution is the most important param-
eter that determines the peak concentration of aminogly-
cosides and is closely related to the extracellular fluid
volume because of the low level of protein binding and
high solubility in water [29]. The volume of distribution
of aminoglycosides is increased in oedematous states,
burns (or extensive skin desquamation) and with capil-
lary leak in severe infection. Children with severe PEM
may have all the three complications: oedema, wide
spread dermatosis and shock due to bacterial infection
[30].
Oedema is a form of ECF seen in both kwashiorkor and
marasmic-kwashiorkor. It has been shown that plasma
protein concentration is often particularly low in children
with oedema. The oedema may clear during nutritional
rehabilitation without any change in serum albumin con-
centration [31].Nutrition & Metabolism 2009, 6:50 http://www.nutritionandmetabolism.com/content/6/1/50
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The bioavalaibility of penicillin [32,33], tobramycin [25],
gentamicin [34], streptomycin [35] and cefoxitin [36]
after intramuscular (i.m) administration did not signifi-
cantly differ in children with kwashiorkor when com-
pared with normal and nutritionally rehabilitated
children. Therefore i.m administration of antibiotics to
children with oedematous PEM (marasmic-kwashiorkor
or kwashiorkor) may be therapeutically acceptable. How-
ever, absolute gross oedema (greater than 30% of body
weight) and shock may reduce bioavailability of i.m anti-
biotics in children with kwashiorkor [37].
Plasma proteins
Following absorption and entry of drugs into the vascular
system, drug molecules frequently bind to plasma pro-
teins. In general, acidic drugs bind to albumin and basic
drugs bind to α1-acid glycoprotein [38]. This is generally
reversible and a state of equilibrium is maintained
between bound and unbound drug. Drugs that are protein
bound do not pass through cell membranes; only the
unbound (free) fraction can distribute into the tissue
compartment [39]. Once in the extravascular space, drug
activity is variable. Drugs may be metabolised or bind to
tissue receptors resulting in a pharmacologic, toxic, or
neutral effect [40].
Hypoproteinaemia is a common feature of PEM [41,42].
Plasma albumin and fractions of the glycoproteins
responsible for binding drugs are decreased [43-45]. As a
result of this decreased protein binding, in theory, there
may be a substantial increase in the plasma free-drug frac-
tions of highly protein-bound drugs and children with
PEM may experience variations in their response to drug
treatment or be at risk of increased drug toxicity [46].
However, in clinical practice, the decreased plasma pro-
tein has not been reported to significantly increase the
plasma free-drug fractions in children with PEM.
Infection and immunity
Malaria, bronchopneumonia and measles are most fre-
quently associated with malnutrition in African children.
In addition, urinary and gastrointestinal tracts infections,
as well as septicaemia may complicate PEM [41,47]. Many
of these infections are due to Gram positive and Gram
negative organisms and are usually implicated in patients
with severe PEM [48-50].
A study has shown that confirmed bacteraemia occurred
in 12% of severe PEM on admissions and complicated
26% of case fatalities with 52% of the deaths occurring
within 48 hours of admission in-spite of treatment with
antibiotics recommended by the WHO [30]. The in vitro
antibiotic susceptibility testing indicated that 85% of the
organisms causing the bacteraemia were susceptible to
ampicillin and gentamicin recommended by the WHO
[21]. Another study that examined susceptibility patterns
among Gram-negative bacilli reported lower levels of iso-
lates fully susceptible to gentamicin (76%); however, in
children with PEM, gentamicin resistance was not found
to be associated with mortality [51]. These deaths upon
adequate treatment of the infection in PEM was attributed
to additional risk factors that may be associated with in-
hospital deaths, which may include alterations in the
pharmacokinetics of the drugs [30]. The clinical efficacy
and toxicity potentials of antibiotics are determined by
their penetration to superficial and deep tissues; therefore,
knowledge of pharmacodynamics and tissue distribution
principles is essential for the rational management of anti-
microbial agents in children with PEM [52].
Changes in gastrointestinal system
Diarrhoea and vomiting are common problems of PEM.
Therefore oral drugs may not be retained, and if it is, the
transit time through the bowel may be decreased. PEM is
associated with various degrees of intestinal malabsorp-
tion [53,54]. Previous work of the Institute of Nutrition of
Central America and Panama (INCAP) has shown that, in
general, the malabsorptive state disappears as the child
recovers [55], but some of the morphological changes per-
sist despite improved nutritional status [56]. However, the
persistent morphological changes after nutritional reha-
bilitation are not associated with any degree of malab-
sorption. PEM is associated with villous atrophy of the
jejunal mucosa [41,56,57] and this may impair drug
absorption [12]. The oral absorption of carbamazepine
[58], chloroquine [59], sulphadiazine [60], and chloram-
phenicol [61] has been reported to decrease significantly
in children with PEM when compared with healthy nor-
mal children. The decreased oral absorption was attrib-
uted to the morphological changes in the jejunum.
Parasitic infestation is a common finding in PEM [56,62].
The influence of intestinal parasitosis on drug absorption
in children with PEM has not been explored. Inspite of
hepatomegaly seen in PEM, liver function tests were
reported normal [63,64]. However, ultrastructure studies
of liver biopsies have shown fatty changes, abnormal
rough endoplasmic reticulum and mitochondria and
decreased peroxisomes [64-66] which were completely
reversible after nutritional rehabilitation. Biotransforma-
tion of drugs occur mostly in the liver via the microsomal
enzyme pathways, therefore hepatic drug metabolism
may be impaired in PEM. The activity of bilirubin-uridyld-
iphosphate (UDP) enzyme involved in the hepatic metab-
olism of chloramphenicol and some other drugs, as well
the hepatic clearance of chloramphenicol, has been
reported to decrease significantly in children with PEM
[67]. Similarly, the plasma level of paraxanthine; a metab-
olite of caffeine has been used to indirectly measure
CYP1A2 (an important hepatic metabolising enzyme)Nutrition & Metabolism 2009, 6:50 http://www.nutritionandmetabolism.com/content/6/1/50
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activity after caffeine administration [68]. The CYP1A2
activity, as well as the hepatic clearance of caffeine, was
significantly decreased in children with kwashiorkor [68].
Changes in renal function
Renal function is a very important determinant of the
pharmacokinetic action of many drugs, but the effects of
malnutrition on renal function have not been studied
extensively. A study that utilised serial measurements of
inulin clearance to measure the renal function of children
with PEM had shown that the glomerular filtration rate
(GFR) and renal blood flow are diminished, particularly
in the presence of dehydration, but revert to normal after
nutritional rehabilitation [69]. However, the amount of
time required for the GFR to return to normal was not
determined. Other studies have utilised less precise meas-
urements of renal function, such as creatinine clearance or
serum creatinine to study the effects of PEM on renal func-
tion. The result was however similar to the previous study
that utilised inulin [70]. The urine of children with PEM is
generally free of protein, glucose and formed elements
such as casts, red blood cells and epithelial cells. Their
blood urea nitrogen and creatinine are normal, indicating
that children with PEM do not have an established renal
failure [71].
Despite lack of evidence of established renal damage in
children with PEM, the oedema observed in marasmic-
kwashiorkor and kwashiorkor has been attributed to the
inability of the kidneys to adequately excrete excess fluid
and sodium [69], as well as to the presence of hypoprotei-
naemia and aflatoxins [8]. The impact of malnutrition on
GFR is most relevant for children receiving drugs prima-
rily excreted by the kidneys, such as the penicillin and
aminoglycosides. While some studies have shown that the
renal clearance of cefoxitin [36] and penicillin [32,33]
were significantly decreased in children with PEM, the
clearance of gentamicin [72,73], amikacin [74], ethambu-
tol [75] and streptomycin [35] were also decreased but
not significantly when compared with clearance in nor-
mal healthy children and after nutritional rehabilitation.
These are drugs that are primarily excreted by the kidney
and none of them showed evidence of toxic plasma con-
centrations, although multiple dose studies were not per-
formed. Similarly, the renal excretion mechanisms of
these drugs and their relationship to the renal function of
children with PEM were not studied. It appears that the
pathophysiological alterations in the renal function of
children with PEM would only cause slight retention of
renally excreted drugs but not up toxic levels that is usu-
ally associated with renal failure [37].
The pharmacokinetics of methotrexate had been studied
in undernourished and well nourished adult patients with
cancer. The drug is primarily excreted by the kidneys; its
elimination half-life was more prolonged in the malnour-
ished than well nourished patients [76]. The author there-
fore suggested that, in malnourished patients, relative
weight; instead of body surface area or body weight, was a
more appropriate parameter to determine drug dosage
and should be used for drug dosing. This suggestion may
indeed hold for dosing of drugs primarily excreted in the
kidneys of children with PEM. Murry et al [77] had further
suggested future studies to evaluate drug dosage adjust-
ments in malnourished patients based on their specific
features, such as GFR.
Changes in cardiovascular system
Children with severe PEM have a smaller and thinner
heart and a lower stroke volume [78]. The inability of the
kidneys to adequately excrete excess fluid and sodium in
marasmic-kwashiorkor and kwashiorkor also adversely
affects the heart. Thus, the circulation is overloaded more
easily than usual. The cell membranes of the heart become
leaky because of oxidative damage [78]. The number of
Na-K pumps in the cell membrane is reduced so as to con-
serve energy and the remaining pumps work more slowly.
Thus intracellular sodium accumulation and potassium
leakages occur, leading to electrolyte and fluid imbalance
[78].
Treatment practices that involve inappropriate fluid ther-
apy may contribute to cardiac failure in PEM [78,79]. Cir-
culatory insufficiency is associated with a prolonged
circulation time and inadequate absorption and distribu-
tion of drugs and nutrients. Oedematous PEM (marasmic-
kwashiorkor and kwashiorkor) are characterised by salt
and water retention [71]. This may contribute to the heart
failure observed in severe PEM [79] and ultimately affect
the effective transportation of drug in the circulatory sys-
tem. Fluid retention would cause expansion of the extra-
cellular fluid volume and may increase the volume of
distribution of water soluble drugs.
Changes in endocrine function
Studies of hormonal influences on drug metabolism,
pharmacokinetics, or pharmacodynamics are still lacking
in human, especially in children with PEM. However,
endocrine system may probably play a major role in drug
metabolism in children. This is because hormones medi-
ate the dramatic physical changes of growth and develop-
ment, and also serve to coordinate metabolic events in
diverse tissues [80].
In the acute phase of PEM, serum insulin levels are
depressed and growth hormone (GH) elevated among
kwashiorkor children [81]. GH values are also elevated in
the marasmic children but the levels were much lower
than those for the kwashiorkor children. While the GH
concentration fell steadily, the insulin rose especiallyNutrition & Metabolism 2009, 6:50 http://www.nutritionandmetabolism.com/content/6/1/50
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among the kwashiorkor children after nutritional rehabil-
itation [81]. The adrenal glands of PEM children are
atrophic at autopsy but plasma cortisol concentrations
were elevated and response to corticotrophin challenge
was unaffected [25]. Cortisol binds to serum proteins;
therefore, hypoalbuminaemia would cause increase free
plasma level of cortisol which may contribute to the
abnormal glucose tolerance and oedema seen in kwash-
iorkor and marasmic-kwshiokor. In animal models,
adrenalectomy and alloxan-induced diabetes abolished
the daily variation in drug metabolism as well as produc-
ing alterations in the basal levels of hepatic microsomal
enzyme activity [82]. Human growth hormone (hGH)
replacement therapy in deficient children has been
reported to substantially prolong the half-life of amobar-
bital [83]. With a substantial increase in plasma GH levels
of PEM children, it would be necessary to study metabo-
lism of amobarbital and other drugs with similar proper-
ties in children with PEM.
Thyroid hormones have been shown to substantially
affect drug elimination in children [84,85]. A study has
shown that the serum triiodothyronine (T3) was
decreased in children with PEM in the face of normal thy-
roxine (T4) and free thyroxine index (FTI) with a corre-
sponding decreased metabolism of antipyrine [86-88].
The low serum triiodothyronine (T3) was attributed to a
reversible defect in extra-thyroidal conversion of T4 to T3
[89], similar to the impairment of biotransformation of
labelled testosterone and oestradiol in patients with ano-
rexia nervosa [90]. Drug metabolism was restored to nor-
mality in the anorexic patients after T3 administration
and nutritional rehabilitation. Interaction between thy-
roid hormones and commonly prescribed drugs has been
well documented [91], resulting in augmentation or
attenuation of the action of either compound. Studies in
animals and cell cultures have shown that thyroid hor-
mones play an important role in the constitutive expres-
sion of the CYP450 enzymes [92], thus potentially
altering the metabolism and effects of a variety of drugs.
P-glycoprotein is expressed in the major organs associated
with drug absorption, distribution and elimination from
the body (e.g. intestine, kidney, liver, skin and the blood-
brain barrier). Expression of intestinal P-glycoprotein in
humans also appears to be influenced by thyroid hor-
mones [93].
Conclusion
Physiological changes in children with PEM are associated
with abnormal disposition of drugs which may necessi-
tate drug dosage modifications. However, the relevance of
the abnormalities to the clinical management of children
with PEM has not been demonstrated conclusively. Also,
the available evidence did not provide any indication for
drug dosage modification in PEM. Considering the high
mortality rate associated with PEM, inappropriate therapy
may be a cause but this has not been proven. Given that
drug retention in PEM could result in adverse events
which may be masked by a constellation of symptoms
and signs of PEM, we therefore advocate more studies on
disposition of drugs in PEM; especially those involving
accurate determination of dosages of drugs frequently
used for their treatment.
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